GENERAL COMMENTS
The manuscript by Henson et al. describes the linkage of community pharmacy based prescription/dispensing data to the national cancer registry of England. This database linkage offers an exciting new opportunity for population-based pharmacoepidemiological research which has -to my knowledge-not existed before with data from the UK. This might become be a valuable resource for epidemiologist working on cancer drug associations. However, the manuscript could benefit by considering the following points: MAJOR 1. In my opinion the biggest limitation of the database so far is the very short available follow-up from April to July 2015 which makes it rather a cross-sectional database than a longitudinal. However, the authors state that more follow-up data will be available in due course. Maybe they could elaborate a bit more on that? And why does the database linkage not start earlier?
2. The authors use the words "prescription" and "dispensing" quite interchangeably throughout the manuscript and for readers it might be confusing to understand if the drug data is based on prescriptions or actual dispensings. This might make a difference for interpretation of results in terms of adherence, since a big chunk of prescribed drugs are usually never picked up at the pharmacy. The authors might want to be consistent in their phrasing throughout the manuscript.
3. In the abstract the authors should add the information on how the two databases are linked (personal identifier).
4. We agree that the current biggest limitation is the time coverage of the prescriptions data, though as we state in the manuscript we are currently in the process of extending the linkage. Updated linked data will be available this year. We are in the process of finalising intermediate timescales, but the objective is to receive updated prescriptions data from NHSBSA on a quarterly basis, with an approximate lag to real-time of six months.
We have adjusted the text to clarify this point.
Data from August 2015 onwards will be available in due course, with updated linked data available in 2018. The objective is to link updated prescriptions data to the cancer registry data on a quarterly basis, with an approximate lag to real-time of six months.
The database linkage does not start earlier as NHS numbers are not available in the prescriptions data prior to April 2015. This was described on page 4 in the following text:
"Since April 2015, NHSBSA expanded the dataset to include NHS number, which is the primary patient identifier in England. This has transformed the data, allowing linkage to other health data, for example national cancer registration Zoledronic Acid_I/V Inf 40mcg/ml 100ml
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According to the BNF online, the indications and dose are as follows.
For Aclasta®

Treatment of Paget's disease of bone
By intravenous infusion, For Adult 5 mg as a single dose, to be administered over at least 15 minutes, at least 500 mg elemental calcium twice daily (with vitamin D) for at least 10 days is recommended following infusion.
Treatment of postmenopausal osteoporosis and osteoporosis in men (including corticosteroidinduced osteoporosis)
By intravenous infusion, For Adult 5 mg once yearly as a single dose, to be administered over at least 15 minutes, in patients with a recent lowtrauma hip fracture, the dose should be given 2 or more weeks following hip fracture repair; before first infusion give 50000-125000 units of vitamin D.
For Zometa® infusion
Reduction of bone damage in advanced malignancies involving bone
By intravenous infusion, For Adult 4 mg every 3-4 weeks, to be administered over at least 15 minutes, calcium 500 mg daily and vitamin D 400 units daily should also be taken.
Hypercalcaemia of malignancy
By intravenous infusion, For Adult 4 mg for 1 dose, to be administered over at least 15 minutes.
Therefore, we are unable to match the information that we have in the linked data to the specific recommended doses and our stated limitation holds.
We will, however, investigate further a linkage to the ATC classification. Thank you for your comment. To clarify, in the linked data at least 24% of the dispensed prescription items per month are from EPS. The remaining items are from FP10. The proportion of prescriptions dispensed as EPS rather than FP10 has increased to approximately 50% in 2018, therefore increasing the quality of the data captured, but not the completeness. This was discussed in the strengths and limitations section, but we have now provided further clarification.
As this resource is
In the linked data (cancer patients diagnosed after 1994), the proportion of dispensed prescription items from FP10 forms, therefore without the day of prescription or prescribers' postcode were 76% in April, 74% in May, 71% in June and 70% in July 2015, which is continually improving. However, the aim of this partnership and data linkage was to understand primary care prescribing activity among cancer patients, and so we do not feel that this is a limitation.
We have included sentences (with appropriate references) to reflect this in the limitations section.
Firstly, prescriptions dispensed in a private setting, prison setting, or without an NHS number recorded are not captured by the data. However, the impact of this is estimated to be less than 3% [23] , less than 1% [24] [25] and 10% of all prescriptions dispensed. In addition, prescriptions that were written but not dispensed, or not submitted by the pharmacy to NHS Prescription Services are not captured, though this is thought to be minimal as the dispenser would not be reimbursed. The linked dispensed prescriptions and cancer registration data resource can also be linked to other datasets held by NCRAS, including Hospital Episodes Statistics (HES) [18] , the RadioTherapy DataSet (RTDS) [19] and the Systemic AntiCancer Therapy (SACT) dataset [20] .
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3. Since the prescription data is near complete, is there any plan to expand the data linkage to other registries? such as MINAP?
As detailed above, the cancer registry holds a wealth of linked data resources. Linkage to other registries and datasets is considered, within the appropriate information governance framework, on an ongoing basis to facilitate our organisational objectives. However, there are no additional partnerships underway that would be relevant to report in this manuscript.
N/A
Editor
Please make it more clear in your manuscript that there are no findings yet to date. Please include Figure  legends at the end of your main manuscript.
These are now included. 
GENERAL COMMENTS
The author response is satisfactory. I have no more comment.
